The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
- Author:
Se Young CHOI
1
;
Hae Jong KIM
;
Hyun Sub CHEONG
;
Soon Chul MYUNG
Author Information
- Publication Type:Original Article
- Keywords: Genetic polymorphism; Human SRD5A2 protein; Prostatic neoplasms
- MeSH: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/*genetics; Aged; Case-Control Studies; Dihydrotestosterone/metabolism; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Logistic Models; Male; Membrane Proteins/*genetics; Middle Aged; Neoplasm Grading; Neoplasm Staging; Odds Ratio; Polymorphism, Single Nucleotide; Prostate-Specific Antigen/blood; Prostatic Neoplasms/epidemiology/*genetics; Republic of Korea/epidemiology; Risk Factors; Testosterone/genetics
- From:Korean Journal of Urology 2015;56(1):19-30
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Steroid 5-alpha reductase type 2 (SRD5A2) modifies testosterone to dihydrotestosterone (DHT) in the prostate. Single-nucleotide polymorphisms (SNPs) of the SRD5A2 gene might affect DHT. We sought to understand the relationship of SRD5A2 SNPs to prostate cancer in the Korean population. MATERIALS AND METHODS: Twenty-six common SNPs in the SRD5A2 gene were assessed in 272 prostate cancer cases and 173 controls. Single-locus analyses were conducted by using conditional logistic regression. Additionally, we performed a haplotype analysis for the SRD5A2 SNPs tested. RESULTS: Among the 20 SNPs and 4 haplotypes, there were no statistically significant results in the prostate cancer patients and the controls. In the logistic analysis of SRD5A2 polymorphisms with prostate-specific antigen (PSA) criteria, two SNPs (rs508562, rs11675297) and haplotype 1 displayed significant results (odds ratio [OR], 1.76; p=0.05; OR, 1.88-2.02; p=0.01-0.04; OR, 0.59; p=0.02, respectively). rs508562, rs11675297, rs2208532, and haplotype 1 (OR, 1.49; p=0.05; OR, 2.02; p=0.05; OR, 2.01; p=0.04; OR, 0.56-0.64, p=0.03-0.04, respectively) had significant associations with Gleason score. rs508562, rs11675297, and haplotype 1 (OR, 1.41-2.34; p=0.004-0.05; OR, 1.74-1.82; p=0.03-0.05; OR, 0.42-0.67; p=0.0005-0.03, respectively) were significantly associated with clinical stage. CONCLUSIONS: We conclude that there was no significant association between SRD5A2 SNPs and the risk of prostate cancer in the Korean population. However, we found that some SNPs and 1 haplotype influenced PSA level, Gleason score, and clinical stage.
